The inconsistencies in the reported data may be due to use of different animal models of Alzheimer's disease, poor blood–brain barrier penetrance of PPAR agonists (i.e. inconsistent drug distribution) and widely variable dosing strategies (Maeshiba et al., 1997; Hemauer et al., 2010). The gene discussed is PPARA; the disease is Alzheimer disease.